Mineralys Therapeutics MLYS 深 滬
等待開盤 08-21 09:30:00 美东时间
25.75
-1.200
-4.45%
華盛通- 最 高26.62
- 今 開26.53
- 成交量 78.52万股
- 最 低 25.30
- 昨 收 26.95
- 總市值 22.76亿
- 52周最高 47.65
- 市盈率 靜 --
- 換手率 0.89%
- 52周最低 22.00
- 委 比 75.00%
- 總股本 8840.69万
- 歷史最高 47.65
- 量 比 0.84
- 振 幅 4.90%
- 歷史最低 5.85
- 每 手 1
- 風險率 6.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | Mineralys Therapeutics 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损2.41亿美元，同比亏损扩大460.5%
华盛资讯8月12日讯，Mineralys Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损2.41亿美元，同比亏损扩大460.5%。
08-12 04:39
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
Mineralys Therapeutics, Inc. will report its second-quarter 2026 financial results after market close on August 11, 2026. A conference call and webcast will be held at 4:30 p.m. ET on the same day. The call can be accessed via the provided domestic and international phone numbers, conference ID 13760792, or the webcast link. Investors can also find the webcast on the company's website. Mineralys focuses on developing treatments for hypertension a...
08-04 12:00
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics announced stock option and restricted stock unit awards to two new non-executive employees under its 2025 Employment Inducement Incentive Award Plan. The awards, granted on July 17 and July 20, 2026, cover a total of 42,800 shares of common stock. The options and restricted stock units will vest over four years, with 25% vesting annually and the remaining shares vesting monthly thereafter, contingent on continued employment...
07-27 20:01
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics presented new data showing that lorundrostat significantly reduced heart failure risk biomarkers in participants with uncontrolled hypertension. The analysis, from the Launch-HTN and Advance-HTN trials, demonstrated coordinated reductions in fibrosis and heart failure biomarkers, suggesting potential modulation of disease pathways. Lorundrostat also increased renin and decreased angiotensinogen, reflecting RAAS engagement. ...
06-14 14:00
Mineralys announces $150 million equity offering and financing
An update from Mineralys Therapeutics, Inc. ( ($MLYS) ) is now available. On Ju...
06-04 04:50
Mineralys Therapeutics prices $150M stock offering
Mineralys Therapeutics (MLYS) has priced an offering of 5.66M shares of its common stock at a price of $26.50 per share. The gross proceeds from the offering are expected to be around $150M. Mineralys...
06-03 18:31
Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds for Royalty Buyback
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)
06-03 18:08
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Mineralys Therapeutics announced the pricing of an underwritten offering of 5,660,378 shares of its common stock at $26.50 per share, expected to raise approximately $150 million in gross proceeds. The offering is set to close on June 4, 2026, subject to customary conditions. Proceeds will be used to partially fund a $200 million upfront payment for repurchasing a royalty obligation under its license agreement with Tanabe Pharma Corporation. BofA...
06-03 10:05
